Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06432140
PHASE3

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency

Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.

View on ClinicalTrials.gov

Summary

This trial includes dose-escalating part (phase 1) and dose confirming part, to prove the safety and efficacy of VGN-R09b to treat patients with severe AADC deficiency

Official title: An Open, Dose-escalating and Dose Confirmation Trial to Evaluate the Safety and Efficacy of VGN-R09b by Intra Putamen Injection in Patients With Severe Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Key Details

Gender

All

Age Range

18 Months - 8 Years

Study Type

INTERVENTIONAL

Enrollment

13

Start Date

2024-07-02

Completion Date

2030-09-20

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

GENETIC

VGN-R09b injection

Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase

Locations (1)

Shanghai

Shanghai, Shanghai Municipality, China